Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain

Driven by a team of scientists and pharmaceutical development specialists, and led by an experienced management team, Biodexa Pharmaceuticals is progressing a pipeline of differentiated therapeutics in areas of high unmet need for the benefit of patients.

The Team

Core to Biodexa Pharmaceuticals strength is its highly experienced and dedicated team.

The Biodexa Pharmaceuticals team benefits from cross-functional expertise including formulation science and pharmaceutical development. With over 10 years’ experience of working together the team has translated multiple programmes from concept to clinic across three distinct technology platforms and apply extensive knowledge and expertise to deliver rapid R&D innovation and value creation.


Biodexa Pharmaceuticals is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Biodexa Pharmaceuticals American Depositary Shares trade on the NASDAQ Capital Market in the United States under the symbol BDRX (CUSIP No. 59564R609).

Investors Area